ZYXI Key Statistics, Chart & Performance
The current stock price of ZYXI is 0.8578 USD. In the past month the price decreased by -27.96%. In the past year, price decreased by -89.56%.
ZYXI Latest News, Press Relases and Analysis
ZYXI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.25 | 210.42B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.61 | 197.21B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.21 | 136.49B | ||
| SYK | STRYKER CORP | 26.51 | 133.51B | ||
| IDXX | IDEXX LABORATORIES INC | 55.71 | 56.10B | ||
| BDX | BECTON DICKINSON AND CO | 13.14 | 54.07B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.65 | 48.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.07 | 37.79B | ||
| RMD | RESMED INC | 25.79 | 37.27B | ||
| DXCM | DEXCOM INC | 35.38 | 25.67B | ||
| PODD | INSULET CORP | 64.33 | 20.68B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.38 | 18.24B |
Related stock screener links
About ZYXI
Company Profile
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. The company is headquartered in Englewood, Colorado and currently employs 1,000 full-time employees. The company went IPO on 2002-11-27. The Company’s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.
Company Info
ZYNEX INC
9655 Maroon Circle
Englewood COLORADO 80112 US
CEO: Thomas Sandgaard
Employees: 1000
Phone: 18004956670
ZYNEX INC / ZYXI FAQ
What does ZYNEX INC do?
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. The company is headquartered in Englewood, Colorado and currently employs 1,000 full-time employees. The company went IPO on 2002-11-27. The Company’s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.
What is the stock price of ZYNEX INC today?
The current stock price of ZYXI is 0.8578 USD. The price increased by 0.91% in the last trading session.
Does ZYXI stock pay dividends?
ZYXI does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZYXI stock?
ZYXI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ZYXI stock?
ZYXI stock is listed on the Nasdaq exchange.
What is the employee count for ZYXI stock?
ZYNEX INC (ZYXI) currently has 1000 employees.
Can you provide the ownership details for ZYXI stock?
You can find the ownership structure of ZYNEX INC (ZYXI) on the Ownership tab.
ZYXI Technical Analysis
ZYXI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZYXI. ZYXI may be in some trouble as it scores bad on both profitability and health.
ZYXI Financial Highlights
Over the last trailing twelve months ZYXI reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS decreased by -540.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -163.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ZYXI Forecast & Estimates
8 analysts have analysed ZYXI and the average price target is 2.91 USD. This implies a price increase of 238.89% is expected in the next year compared to the current price of 0.8578.
For the next year, analysts expect an EPS growth of -1584.67% and a revenue growth -52.33% for ZYXI